© 2006 American Academy of Neurology Practice Parameter: Neuroprotective Strategies and Alternative Therapies for Parkinson’s Disease (An Evidence-Based.

Slides:



Advertisements
Similar presentations
Medical Library & Peyton T. Anderson Learning Resources Center Macon, GA Memorial University Medical Center Health Sciences.
Advertisements

New England Journal of Medicine October 18;367: Relapse Risk after Discontinuation of Risperidone in Alzheimer’s disease Molly Moncrieff.
Improving The Clinical Care of Children and Adolescents With Mild Traumatic Brain Injury Madeline Joseph, MD, FACEP, FAAP Professor of Emergency Medicine.
The Cochrane Reviews of Acupuncture Doris Hubbs, MD, FACP April 26, 2013.
Clinical Policy / Practice Guideline Development Andy Jagoda, MD, FACEP Professor of Emergency Medicine Mount Sinai School of Medicine New York, New York.
Accessing Sources Of Evidence For Practice Introduction To Databases Karen Smith Department of Health Sciences University of York.
1.A 33 year old female patient admitted to the ICU with confirmed pulmonary embolism. It was noted that she had elevated serum troponin level. Does this.
Information Resources for Evidence-Based Medicine A Review 3 rd Year Family Medicine Clerkship - EBM.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2014.
By Dr. Ahmed Mostafa Assist. Prof. of anesthesia & I.C.U. Evidence-based medicine.
Long-term predictive value of assessment of coronary atherosclerosis by contrast- enhanced coronary computed tomography angiography: meta- analysis and.
Cohort Studies Hanna E. Bloomfield, MD, MPH Professor of Medicine Associate Chief of Staff, Research Minneapolis VA Medical Center.
1 Tolvaptan for the Treatment of Hyponatremia Aliza Thompson, MD Medical Officer Cardiovascular and Renal Drugs Advisory Committee Meeting June 25, 2008.
Chronic Pain A Review of the Literature. Meade Study: BMJ 1990 A British ten year study concluded that chiropractic treatment was significantly more effective,
Developing Research Proposal Systematic Review Mohammed TA, Omar Ph.D. PT Rehabilitation Health Science.
Background Information : Projected prevalence of arthritis is expected to increase from 2.9 million to 6.5 million Canadians, a rise of 124% (Badley.
What is a Clinical Trial (alpha version) John M. Harris Jr., MD President Medical Directions, Inc.
QCOM Library Resources Rick Wallace, Nakia Woodward, Katie Wolf.
Slide 1 Long-Term Care (LTC) Collaborative PIP: Medication Review Tuesday, October 29, 2013 Presenter: Christi Melendez, RN, CPHQ Associate Director, PIP.
Systematic Reviews.
Evidence Based Medicine Meta-analysis and systematic reviews Ross Lawrenson.
Evidence-Based Public Health Nancy Allee, MLS, MPH University of Michigan November 6, 2004.
Practice Parameter: Immunotherapy for Guillain-Barré syndrome
Landmark Trials: Recommendations for Interpretation and Presentation Julianna Burzynski, PharmD, BCOP, BCPS Heme/Onc Clinical Pharmacy Specialist 11/29/07.
Clinical Writing for Interventional Cardiologists.
RevMan for Registrars Paul Glue, Psychological Medicine What is EBM? What is EBM? Different approaches/tools Different approaches/tools Systematic reviews.
Clinical Information Resources Sandra A. Martin, M.L.I.S. Health Sciences Resource Coordinator Instructor of Library Services John Vaughan Library Room.
Wipanee Phupakdi, MD September 15, Overview  Define EBM  Learn steps in EBM process  Identify parts of a well-built clinical question  Discuss.
بسم الله الرحمن الرحيم جامعة أم درمان الإسلامية كلية الطب و العلوم الصحية - قسم طب المجتمع مساق البحث العلمي / الدفعة 21 Basics of Clinical Trials.
The Occupational Therapist and Huntington’s Disease
How To Design a Clinical Trial
Sifting through the evidence Sarah Fradsham. Types of Evidence Primary Literature Observational studies Case Report Case Series Case Control Study Cohort.
EBM --- Journal Reading Presenter :呂宥達 Date : 2005/10/27.
Is the conscientious explicit and judicious use of current best evidence in making decision about the care of the individual patient (Dr. David Sackett)
EVALUATING u After retrieving the literature, you have to evaluate or critically appraise the evidence for its validity and applicability to your patient.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November-December 2012.
G. Biondi Zoccai – Ricerca in cardiologia What to expect? Core modules IntroductionIntroduction Finding out relevant literatureFinding out relevant literature.
European Patients’ Academy on Therapeutic Innovation Ethical and practical challenges of organising clinical trials in small populations.
بسم الله الرحمن الرحیم.
©2014 American Academy of Neurology. Report of the Guideline Development Subcommittee of the American Academy of Neurology Systematic Review: Efficacy.
© 2012 American Academy of Neurology IV IMMUNOGLOBULIN IN THE TREATMENT OF NEUROMUSCULAR DISORDERS Report of the Therapeutics and Technology Assessment.
Practice Parameter: Use of Epidural Steroid Injections to Treat Radicular Lumbosacral Pain (An Evidence-Based Review) American Academy of Neurology (AAN)
Practice Parameter: Treatment of Nervous System Lyme Disease (An Evidence-Based Review) American Academy of Neurology (AAN) Quality Standards Subcommittee.
© 2006 American Academy of Neurology Practice Parameter: Evaluation and Treatment of Depression, Psychosis and Dementia in Parkinson Disease: An Evidence-Based.
©2015 American Academy of Neurology. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society.
© 2006 American Academy of Neurology Practice Parameter: Treatment of Parkinson Disease with Motor Fluctuations and Dyskinesia (An Evidence-Based Review)
Evidence-Based Medicine: A Basic Primer Kevin Bradford, M.L.S. Clinical Information Librarian Instructor Medical College of Georgia April 2007.
© 2012 American Academy of Neurology Evidence-based Guideline: Steroids and antivirals for Bell palsy Report of the Guideline Development Subcommittee.
American Academy of Neurology © 2008 Practice Parameter: Assessing Patients in a Neurology Practice for Risk of Falls (An Evidence-Based Review) American.
Evidence Report: Neutralizing Antibodies to Interferon: An Assessment of Their Clinical and Radiological Impact American Academy of Neurology Therapeutic.
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
Information Mastery Information management Determine usefulness Understand sources (jungle) Make decisions with your patient.
© 2006 American Academy of Neurology Practice Parameter: Diagnosis and Prognosis of New Onset Parkinson Disease (An Evidence-Based Review) American Academy.
Efficacy of Colchicine When Added to Traditional Anti- Inflammatory Therapy in the Treatment of Pericarditis Efficacy of Colchicine When Added to Traditional.
The Efficacy of Dabigatran versus Warfarin for Stroke Prevention in Patients With Atrial Fibrillation: Systematic Review Karim Bouferrache Pacific University.
A quick reference to literature searches
Use of fMRI in the Presurgical Evaluation of Patients with Epilepsy
How To Design a Clinical Trial
Effects of Uric acid- lowering therapy on renal outcomes: a systematic review and meta-analysis Nephrol Dial Transplant (2014) 29: Vaughan Washco.
NURS3030H NURSING RESEARCH IN PRACTICE MODULE 7 ‘Systematic Reviews’’
Evidence-Based Practice I: Definition – What is it?
Critical Reading of Clinical Study Results
Alcohol, Other Drugs, and Health: Current Evidence May-June, 2018
Pearls Presentation Use of N-Acetylcysteine For prophylaxis of Radiocontrast Nephrotoxicity.
Information Pyramid UpToDate, Dynamed, FIRSTConsult, ACP PIER
1 Verstovsek S et al. Proc ASH 2012;Abstract Cervantes F et al.
IMPACT OF PHARMACIST DELIVERED CARE IN THE COMMUNITY PHARMACY SETTING
What is a review? An article which looks at a question or subject and seeks to summarise and bring together evidence on a health topic. Ask What is a review?
Effectiveness of Systemic Treatments for Pyoderma Gangrenosum: A Systematic Review of Observational Studies & Clinical Trials ACR Partridge1, JW Bai1,
Evidence-Based Public Health
Presentation transcript:

© 2006 American Academy of Neurology Practice Parameter: Neuroprotective Strategies and Alternative Therapies for Parkinson’s Disease (An Evidence-Based Review) American Academy of Neurology Quality Standard Subcommittee O. Suchowersky, MD; G. Gronseth, MD; J. Perlmutter, MD; S. Reich, MD; T. Zesiewicz, MD; W.J. Weiner, MD

© 2006 American Academy of Neurology The AAN develops these presentation slides as educational tools for neurologists and other health care practitioners. You may download and retain a single copy for your personal use. Please contact to learn about options for sharing this content beyond your personal

© 2006 American Academy of Neurology Presentation Objectives To define key issues in the management of Parkinson’s disease (PD) relating to neuroprotective strategies and alternative treatments To make evidence-based recommendations

© 2006 American Academy of Neurology Overview Background and epidemiology Gaps in PD care AAN guideline process Neuroprotective strategies Alternative treatments Summary Recommendations for future research

© 2006 American Academy of Neurology Background PD a neurodegenerative disorder Classic symptoms: –Bradykinesia –Rigidity –Rest tremor Strategies to delay onset or slow progression – important considerations in overall treatment

© 2006 American Academy of Neurology Descriptive Epidemiology of Parkinson Syndrome Incidence –5–24/10 5 worldwide (ref) –20.5/10 5 USA (ref) Prevalence –57–371/10 5 worldwide (ref) –300/10 5 USA/Canada (Strickland & Bertoni, 2004) –Prevalence of PS/PD rising slowly with aging population

© 2006 American Academy of Neurology Gaps in PD Care Widespread fear that levodopa is neurotoxic and speeds up disease symptoms Neuroprotection: Is there anything that will help slow the advancement of the disease?

© 2006 American Academy of Neurology Gaps in PD Care Many patients and caregivers use alternative or complementary medications and vitamins –63% of patients use nutritional supplements, but less than 50% report this to their physician (Rajendran et al., 2001) –Only 4% are aware of possible drug interactions (Carter et al., 2003)

© 2006 American Academy of Neurology Seeking Answers How do we find the answers to the questions that arise in daily practice? In order to keep up to date, need to read 29 articles a day, 365 days a year (Didsbury, 2003) Or find someone who has found and summarized the relevant data for you

© 2006 American Academy of Neurology American Academy of Neurology Guideline Process Clinical Question Evidence Conclusions Recommendations

© 2006 American Academy of Neurology Clinical Question Question should address an area of quality concern, controversy, confusion, or variation in practice Question must be answerable with sufficient scientific data –Potential to improve clinical care and patient outcomes

© 2006 American Academy of Neurology Literature Search/Review: Rigorous, Comprehensive, Transparent Search Review abstracts Review full text Select articles Relevant Complete

© 2006 American Academy of Neurology AAN Classification for Evidence All studies rated Class I, II, III, or IV Therapeutic Studies –Randomization, control, blinding Diagnostic Studies –Comparison to gold standard; spectrum Prognostic Studies

© 2006 American Academy of Neurology AAN Level of Recommendations A = Established as effective, ineffective, or harmful for the given condition in the specified population B = Probably effective, ineffective, or harmful for the given condition in the specified population C = Possibly effective, ineffective, or harmful for the given condition in the specified population U = Data is inadequate or conflicting; given current knowledge, treatment is unproven

© 2006 American Academy of Neurology AAN Level of Recommendations A = Requires two consistent Class I studies B = Requires one Class I study or two consistent Class II studies C = Requires one Class II study or two consistent Class III studies U = Studies not meeting criteria for Class I through Class III

© 2006 American Academy of Neurology Clinical Questions 1.Are there any therapies that can slow progression of PD? 2.Are there any nonstandard, pharmacologic or nonpharmacologic therapies that have been shown to improve motor function in PD?

© 2006 American Academy of Neurology Methods Literature Search: –MEDLINE, EMBASE, CINHAL, and Cochrane Database of Systematic Reviews ( ) Only articles written in English included –Second MEDLINE search (1966 through Aug. 2004) Followed by a secondary search extending to January 2005 using the bibliographies of retrieved articles

© 2006 American Academy of Neurology Methods At least two authors reviewed each full article Risk of bias determined using the classification of evidence for each study (Class I–IV) Strength of practice recommendations linked directly to level of evidence (Level A–U) Conflicts of interests disclosed

© 2006 American Academy of Neurology Literature Search/Review: Neuroprotective Strategies 11 articles 112 articles Exclusion criteria: -Articles dealing only with symptomatic benefit -Articles with at least 6 months of follow up -Articles that were off topic -Review articles

© 2006 American Academy of Neurology Literature Search/Review: Alternative Therapies 22 articles 167 articles Exclusion criteria: -Studies including at least 10 subjects with treatment of at least 1 week duration -Articles that were off topic -Review articles

© 2006 American Academy of Neurology Neuroprotective Strategies

© 2006 American Academy of Neurology PD Neuroprotection Challenge in defining and measuring neuroprotection Potential clinical surrogate markers not validated Neuroimaging weakened by confounding Long-term follow-up required to test possible neuroprotective benefit

© 2006 American Academy of Neurology Clinical Question 1 Are there any therapies that can slow progression of PD?

© 2006 American Academy of Neurology PD Neuroprotection Neuroprotective therapies considered: –Vitamin E –Riluzole –Coenzyme Q10 –Levodopa –Pramipexole –Ropinirole –Other

© 2006 American Academy of Neurology Neuroprotective Strategies 11 articles met inclusion criteria for clinical question –7 Class 1 studies –1 Class II study –3 Class IV studies

© 2006 American Academy of Neurology PD Neuroprotection: Vitamin E Two articles identified Class IV study (Fahn, 1992) –Nonrandomized, unblinded study –No independent assessment –Suggested slower rate of progression in patients with early PD treated with vitamin E (3,200 IU/day) combined with vitamin C (3,000 mg/day)

© 2006 American Academy of Neurology PD Neuroprotection: Vitamin E Class I trial: DATATOP (PSG, 1993) –Randomized, double-blind, prospective –800 patients randomized to a dose of 2,000 IU of vitamin E/day or placebo –Followed for 14 ± 6 months –Primary endpoint: onset of disability requiring use of levadopa –No difference between tocopherol and placebo groups in the average time to required levodopa (hazard ratio 0.91, 95% CI.74 to 1.12)

© 2006 American Academy of Neurology PD Neuroprotection: Recommendation for Vitamin E For patients with PD, treatment with 2,000 units of vitamin E should not be considered for neuroprotection (Level B)

© 2006 American Academy of Neurology PD Neuroprotection: Levodopa One Class I study (PSG, 2004) –Double-blinded, controlled trial –Randomized 361 patients with PD to placebo or levodopa (150mg/day, 300 mg/day, or 600 mg/day) –Primary outcome: masked assessment of change in UPDRS from baseline after 40 weeks of treatment and 2-week washout –Patients randomized to all levodopa doses: significantly better UPDRS scores than patients on placebo

© 2006 American Academy of Neurology PD Neuroprotection: Levodopa Parkinson Study Group 2004, NEJM.

© 2006 American Academy of Neurology PD Neuroprotection: Recommendation for Levodopa Levodopa may be considered for initial treatment of PD (Level B) –9 months –Does not accelerate disease progression –Safe No long term evidence to recommend levodopa for neuroprotection (Level U)

© 2006 American Academy of Neurology PD Neuroprotection: Rasagiline

© 2006 American Academy of Neurology Recommendations for Neuroprotection Insufficient evidence for neuroprotection (Level U): –Coenzyme Q10 –Rasagile –Riluzole –Selegiline

© 2006 American Academy of Neurology Recommendations for Neuroprotection Insufficient evidence for neuroprotection (Level U): –Amantadine –Ropinirole –Pramipexole –Thalamotomy

© 2006 American Academy of Neurology Alternative Therapies

© 2006 American Academy of Neurology Clinical Question 2 Are there any non-standard pharmacological or nonpharmacological therapies that have been shown to improve motor function in PD?

© 2006 American Academy of Neurology Alternative Therapies Use of complementary medication and treatment common in patients with PD –40% of patients in the United States and 54% of patients in the United Kingdom use herbs, vitamins, massage and acupuncture (Rajendran et al., 2001; Ferry et al., 2002)

© 2006 American Academy of Neurology Alternative Therapies Foods: –Mucuna pruriens (cowhage or velvet bean) –Vicia faba (broad or fava bean) Vitamins: –Vitamin C –Folic acid, pyridoxine –Vitamin E Acupuncture

© 2006 American Academy of Neurology Alternative Therapies Manual Therapy –Chiropractic manipulation –Osteopathic manipulation –Trager therapy Exercise therapy Speech therapy

© 2006 American Academy of Neurology Alternative Therapies 22 articles met inclusion criteria for clinical question –2 Class 1 studies –15 Class II study –2 Class III studies –3 Class IV studies

© 2006 American Academy of Neurology Recommendations for Alternative Therapies in PD Insufficient evidence (Level U): –M pruriens –Acupuncture –Biofeedback –Manual therapy –Alexander technique

© 2006 American Academy of Neurology Exercise Therapy in PD Multidisciplinary rehabilitation Music therapy Treadmill training Balance training “Cued” exercise training

© 2006 American Academy of Neurology Exercise Therapy in PD Author Cohort size Outcome VariablesTreatmentDuration Wade et al PDQ-39, SC-36, peg test, walking multidisciplinary rehab vs. placebo 1 x per week x 6 weeks, FU 48 weeks Marchese et al UPDRScued vs. non- cued exercises 3 x per week x 6 weeks, FU 12 weeks Miyai et al UPDRS, ambulation BWSTT vs. physiotherapy 3 x per week x 4 weeks, FU 8 weeks

© 2006 American Academy of Neurology Exercise Therapy in PD Author Cohort size Outcome VariablesTreatmentDuration Miyai et al UPDRS, ambulation BWSTT vs. physiotherapy 3 x per week x 4 weeks, FU 6 months Hirsch et al balance, falls, strength Balance/resistanc e vs. balance 3 x per week x 10 weeks, FU 14 weeks Pachetti et al UPDRS, PDQualif Music therapy vs. physical therapy 1 x per week x 3 months, FU 5 months Comella et al UPDRS, depression General exercise vs. placebo 3 x per week x 1 month, FU 12 months

© 2006 American Academy of Neurology Recommendation for Exercise Therapy in PD Exercise therapy may be considered to improve function (Level C) –Results in improvement in UPDRS –Decrease in falls

© 2006 American Academy of Neurology Exercise Therapy in PD No specific exercise program shown to be superior to another Benefit not sustained after exercise is discontinued

© 2006 American Academy of Neurology Speech Therapies in PD For patients with PD complicated by dysarthria, speech therapy may be considered to improve speech volume (Level C) –5 trials identified No specific therapy shown to be superior to another

© 2006 American Academy of Neurology Summary Levodopa does not appear to accelerate disease progression No treatment has been shown to be neuroprotective No evidence that vitamin or food additives can improve motor function in PD

© 2006 American Academy of Neurology Summary Exercise may be helpful in improving motor function Speech therapy may be helpful in improving speech volume No manual therapy has been shown to be helpful in the treatment of motor symptoms

© 2006 American Academy of Neurology Recommendations for Future Research Reliable and validated surrogated endpoints that mirror nigrostriatal dopaminergic neuron loss Accurate early diagnosis and improved knowledge of disease progression

© 2006 American Academy of Neurology Recommendations for Future Research Development of methods to identify presymptomatic patients for clinical trials Innovative trials with long-term follow-up Studies to demonstrate safety or effectiveness of neuroprotective therapies

© 2006 American Academy of Neurology To access the full guideline please visit: AAN.com/Guidelines Neurology® April 11, :

© 2006 American Academy of Neurology Questions or comments?

© 2006 American Academy of Neurology Thanks for your participation!